0001016169false00010161692021-11-042021-11-0400010161692021-08-172021-08-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________________
FORM 8-K
_________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2021
_________________________________________________________________
ANTARES PHARMA, INC.
(Exact name of registrant as specified in its charter)
_________________________________________________________________
Delaware 001-32302 41-1350192
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
100 Princeton South, Suite 300, Ewing, NJ
08628
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (609) 359-3020
Not Applicable
(Former name or former address, if changed since last report.)
_________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share ATRS NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o



Item 2.02    Results of Operations and Financial Condition
On November 4, 2021, Antares Pharma, Inc. (the “Company”) issued a press release announcing its operating and financial results for the third quarter ended September 30, 2021. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific references in such filing.
Item 9.01    Financial Statements and Exhibits
(d)     Exhibits

The following exhibits are being furnished herewith:
Exhibit
No.
Description
 
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANTARES PHARMA, INC.
(Registrant)
Date:
November 4, 2021 By: /s/ Fred M. Powell
Name: Fred M. Powell
Title: Executive Vice President and Chief Financial Officer

Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Antares Pharma Charts.
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Antares Pharma Charts.